Home โบ Lung Cancer
Lung Cancer clinical trials recruiting in the U.S.
347 studies for Lung Cancer are recruiting participants at sites across the United States.
Lung cancer forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women.
Cities with the most studies
- Houston, TX78 studies
- Boston, MA62 studies
- New York City, NY60 studies
- Los Angeles, CA45 studies
- Washington, DC41 studies
- Chicago, IL41 studies
- Arlington, VA40 studies
- Baltimore, MD40 studies
- Nashville, TN40 studies
- St. Louis, MO39 studies
- Columbus, OH36 studies
- Philadelphia, PA36 studies
- Seattle, WA33 studies
- Durham, NC32 studies
- Tampa, FL29 studies
- Atlanta, GA29 studies
- Dallas, TX27 studies
- Portland, OR26 studies
- Cleveland, OH26 studies
- San Antonio, TX26 studies
- Baldwin Park, CA24 studies
- Edison, NJ24 studies
- San Francisco, CA23 studies
- San Diego, CA23 studies
- Pittsburgh, PA23 studies
- New Haven, CT23 studies
- Sacramento, CA22 studies
- Ann Arbor, MI22 studies
- Queens, NY22 studies
- Salt Lake City, UT21 studies
- Detroit, MI21 studies
- Milwaukee, WI21 studies
- Orlando, FL21 studies
- Miami, FL20 studies
- Minneapolis, MN20 studies
- Rochester, MN20 studies
- Kansas City, MO19 studies
- Evanston, IL19 studies
- Oklahoma City, OK19 studies
- Aurora, CO19 studies
By state
- Alabama16 studies
- Alaska7 studies
- Arizona34 studies
- Arkansas19 studies
- California112 studies
- Colorado38 studies
- Connecticut31 studies
- Delaware11 studies
- District of Columbia27 studies
- Florida76 studies
- Georgia40 studies
- Hawaii8 studies
- Idaho11 studies
- Illinois62 studies
- Indiana25 studies
- Iowa19 studies
- Kansas21 studies
- Kentucky26 studies
- Louisiana16 studies
- Maine12 studies
- Maryland56 studies
- Massachusetts75 studies
- Michigan45 studies
- Minnesota42 studies
- Mississippi14 studies
- Missouri44 studies
- Montana14 studies
- Nebraska20 studies
- Nevada11 studies
- New Hampshire12 studies
- New Jersey42 studies
- New Mexico15 studies
- New York93 studies
- North Carolina50 studies
- North Dakota15 studies
- Ohio67 studies
- Oklahoma20 studies
- Oregon31 studies
- Pennsylvania57 studies
- Rhode Island6 studies
- South Carolina19 studies
- South Dakota15 studies
- Tennessee58 studies
- Texas101 studies
- Utah25 studies
- Vermont7 studies
- Virginia57 studies
- Washington43 studies
- West Virginia11 studies
- Wisconsin31 studies
Recently updated studies
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT07519655Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RecruitingObservational study
Ages 3 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT01441089A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT07099898Collection of Blood From Patients With Cancer
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT00034216SPARC - Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based Classifier
RecruitingObservational studyHealthy volunteers welcome
Ages 21 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT07460440Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT06780098A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT07286149Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT07476287Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT06498635Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT04267848A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT07154290A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT06312137Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT07489066A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
RecruitingPhase 3
Ages 18 to 100 ยท All sexes ยท Updated Sep 25, 2026 ยท NCT05920356Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT07222566A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT06172478This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT06758401Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal, Gynecological, Breast, or Lung Cancer
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT06855524Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Sep 24, 2026 ยท NCT04181060Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
RecruitingPhase 3
Ages 70 and older ยท All sexes ยท Updated Sep 24, 2026 ยท NCT06096844A Registry for People With Lung Cancer
RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Sep 24, 2026 ยท NCT06424327Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
RecruitingPhase 2
Ages 18 to 95 ยท All sexes ยท Updated Sep 23, 2026 ยท NCT05061550A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Sep 23, 2026 ยท NCT06618287A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
RecruitingPhase 2/3
Ages 18 and older ยท All sexes ยท Updated Sep 23, 2026 ยท NCT07063745Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
RecruitingObservational study
Ages 2 to 120 ยท All sexes ยท Updated Sep 23, 2026 ยท NCT00242723From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.